Mr. Gero became Chairman of Orthofix International N.V. on Jan. 1, 2005, and has been a Director of Orthofix International N.V. since 1998. Mr. Gero became a Director of AME Inc. in 1990. He is a Director of Intrusion Inc., Drew Industries Inc. and Greenleaf Inc. as well as being a private investor.
Dr. Jordan became a non-executive Director of Orthofix International N.V. in December 2004. Most recently, Dr. Jordan served as a group president at CR Bard, Inc., a medical device company, where he had strategic and operating responsibilities for Bard's global oncology business and functional responsibility for all of Bard's research and development. Dr. Jordan earned a Ph.D. in organic chemistry from Georgetown University as well as an MBA from Fairleigh Dickinson University. He also currently serves on the boards of Specialized Health Products International, Inc., Xillix Technologies Corporation and EsophyX, Inc.
Mr. Mainelli was elected to the Orthofix International Board of Directors in 2009. He currently serves as the President and CEO of Active Implants Corporation. He was formerly an executive officer at Stryker Corporation, serving as President-Stryker Spine, President-Stryker Japan and initially as VP-Corporate Development and Assistant to the Chairman. Prior to joining Stryker he was a marketing and product management executive in the Global Magnetic Resonance Business at GE Medical Systems, now called GE Healthcare. Mr. Mainelli holds a MBA from the University of Chicago, a MSE from the University of Pennsylvania and a BSME from Northeastern University.
Ms. Sainz was reappointed to the Orthofix International Board of Directors in November 2012. She is currently serving as the President, Chief Executive Officer, and Director of CardioKinetix Inc.. Prior to that, Ms. Sainz was the President and Chief Executive Officer of Concentric Medical, Inc. up to and during its acquisition by Stryker Corporation in October 2011. She had previously served as the President of the Cardiac Surgery division of Guidant Corporation/Boston Scientific. Ms. Sainz received an M.A. in Languages from the University Complutense in Madrid, Spain and a Masters in International Management from the American Graduate School of International Management.
Mr. Scoon joined the Orthofix Board of Directors in 2011. Mr. Scoon also serves as Chairman of the Board of Directors of Tufts Health Plan, where he has been a director since 1981, as Chairman of the Board of Trustees of Allianz Funds and as Chairman of the Audit Committee of AMAG Pharmaceuticals and Cardiokine. He has previously served as a board member with NitroMed and Inotek Pharmaceuticals and worked as a top executive with Tom's of Maine, Sun Life Financial US and the Liberty Funds Group of Boston. Mr. Scoon has taught accounting courses at the University of Wisconsin Madison and Tufts University School of Medicine. He holds a bachelor's degree from the University of Wisconsin and an MBA from Harvard Business School.
Dr. von Wartburg became a non-executive Director of Orthofix International N.V. in June 2004. He is an attorney and has practiced privately in his own law firm in Basel, Switzerland since 1999, specializing in life sciences law. He has also been a professor of administrative law and public health policy at the Saint Gall Graduate School of Economics in Switzerland for 25 years. Previously, he held top management positions with Ciba Pharmaceuticals and Novartis at their headquarters in Basel, Switzerland. In addition, Mr. von Wartburg currently serves as a Director on the board of Nymox Pharmaceutical Corporation.
Director, Chairman of the Nominating and Governance Committee
Mr. Weisshaar became a non-executive Director of Orthofix International N.V. in December 2004. Most recently, Mr. Weisshaar has served as Chief Operating Officer and strategy advisor for Sensatex, Inc. Also, Mr. Weisshaar spent 12 years as a corporate officer at Becton Dickson, a medical device company, where at different times he was responsible for global businesses in medical devices and diagnostic products and served as Chief Financial Officer and Vice President, Strategic Planning. Mr. Weisshaar earned a bachelor of science degree from MIT and an MBA from Harvard University. He currently also serves on the board of Casmed Corporation.